Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
1 599
Price to sales ratio
83.86

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
145
SNY
Sanofi - American Depositary Shares
44.84 USD-1.28%-0.93%-1.32%-9.23%109.36 B USD
149
GSK
GSK plc American Depositary Shares
50.28 USD-2.26%-2.60%-6.77%+14.66%108.49 B USD
440
BIIB
Biogen Inc. - Common Stock
221.50 USD+0.19%+1.72%+5.06%+67.17%32.73 B USD
1128
CGON
CG Oncology, Inc. - Common stock
79.01 USD+0.75%+0.41%+7.78%+81.38%7.00 B USD

Frequently asked questions about BeOne Medicines Ltd. American Depositary Shares

What is the BeOne Medicines Ltd. American Depositary Shares stock price today?

The current price of BeOne Medicines Ltd. American Depositary Shares (ONC) is 372.49. Over the past 24 hours, the stock has changed by -0.88%. Follow the ONC chart for real-time price dynamics.

What is the stock ticker of BeOne Medicines Ltd. American Depositary Shares?

BeOne Medicines Ltd. American Depositary Shares trades under the ticker ONC. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is BeOne Medicines Ltd. American Depositary Shares stock going up?

ONC has changed by -0.67% over the last week, +13.22% over the last month, and +17.99% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of BeOne Medicines Ltd. American Depositary Shares?

BeOne Medicines Ltd. American Depositary Shares currently has a market capitalization of 42.35 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were BeOne Medicines Ltd. American Depositary Shares earnings last quarter?

Last quarter, BeOne Medicines Ltd. American Depositary Shares reported earnings of 0.16 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was BeOne Medicines Ltd. American Depositary Shares revenue for the last quarter?

BeOne Medicines Ltd. American Depositary Shares reported quarterly revenue of 1.71 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was BeOne Medicines Ltd. American Depositary Shares net income for the last quarter?

BeOne Medicines Ltd. American Depositary Shares reported net income of 237.01 M for the last quarter. The previous quarter showed 227.36 M, which means net income changed by +4.24%.

How many employees does BeOne Medicines Ltd. American Depositary Shares have?

As of the latest available data, BeOne Medicines Ltd. American Depositary Shares has 12 K employees. Workforce size can provide additional context about the company's scale and operations.

What is BeOne Medicines Ltd. American Depositary Shares EBITDA?

BeOne Medicines Ltd. American Depositary Shares EBITDA is 540.09 M, and its EBITDA margin is 31.68%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy BeOne Medicines Ltd. American Depositary Shares stock?

You can buy BeOne Medicines Ltd. American Depositary Shares (ONC) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in BeOne Medicines Ltd. American Depositary Shares stock?

Investing in BeOne Medicines Ltd. American Depositary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ONC chart and related analysis on metatrader.com as part of your research.

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.